471 related articles for article (PubMed ID: 17257461)
1. The potential for CETP inhibition to reduce cardiovascular disease risk.
Ansell B; Hobbs FD
Curr Med Res Opin; 2006 Dec; 22(12):2467-78. PubMed ID: 17257461
[TBL] [Abstract][Full Text] [Related]
2. Targeting cholesteryl ester transfer protein for the prevention and management of cardiovascular disease.
Barter PJ; Kastelein JJ
J Am Coll Cardiol; 2006 Feb; 47(3):492-9. PubMed ID: 16458126
[TBL] [Abstract][Full Text] [Related]
3. HDL metabolism and CETP inhibition.
Barkowski RS; Frishman WH
Cardiol Rev; 2008; 16(3):154-62. PubMed ID: 18414186
[TBL] [Abstract][Full Text] [Related]
4. [HDL and CETP in atherogenesis].
Pöss J; Böhm M; Laufs U
Dtsch Med Wochenschr; 2010 Feb; 135(5):188-92. PubMed ID: 20082258
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic elevation of HDL-cholesterol to prevent atherosclerosis and coronary heart disease.
Chapman MJ
Pharmacol Ther; 2006 Sep; 111(3):893-908. PubMed ID: 16574234
[TBL] [Abstract][Full Text] [Related]
6. Targeting residual cardiovascular risk: raising high-density lipoprotein cholesterol levels.
Hausenloy DJ; Yellon DM
Heart; 2008 Jun; 94(6):706-14. PubMed ID: 18480348
[TBL] [Abstract][Full Text] [Related]
7. Cholesteryl ester transfer protein (CETP) inhibition beyond raising high-density lipoprotein cholesterol levels: pathways by which modulation of CETP activity may alter atherogenesis.
Klerkx AH; El Harchaoui K; van der Steeg WA; Boekholdt SM; Stroes ES; Kastelein JJ; Kuivenhoven JA
Arterioscler Thromb Vasc Biol; 2006 Apr; 26(4):706-15. PubMed ID: 16439711
[TBL] [Abstract][Full Text] [Related]
8. A Translational Medicine perspective of the development of torcetrapib: Does the failure of torcetrapib development cast a shadow on future development of lipid modifying agents, HDL elevation strategies or CETP as a viable molecular target for atherosclerosis? A case study of the use of biomarkers and Translational Medicine in atherosclerosis drug discovery and development.
Zhao L; Jin W; Rader D; Packard C; Feuerstein G
Biochem Pharmacol; 2009 Aug; 78(4):315-25. PubMed ID: 19539799
[TBL] [Abstract][Full Text] [Related]
9. CETP inhibition in cardiovascular risk management: a critical appraisal.
Dullaart RP; Dallinga-Thie GM; Wolffenbuttel BH; van Tol A
Eur J Clin Invest; 2007 Feb; 37(2):90-8. PubMed ID: 17217373
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of CETP as a novel therapeutic strategy for reducing the risk of atherosclerotic disease.
Shah PK
Eur Heart J; 2007 Jan; 28(1):5-12. PubMed ID: 17121756
[TBL] [Abstract][Full Text] [Related]
11. Cholesteryl ester transfer protein inhibition in cardiovascular risk management: ongoing trials will end the confusion.
Kappelle PJ; van Tol A; Wolffenbuttel BH; Dullaart RP
Cardiovasc Ther; 2011 Dec; 29(6):e89-99. PubMed ID: 20645987
[TBL] [Abstract][Full Text] [Related]
12. Refocusing on use of cholesteryl ester transfer protein inhibitors.
Kastelein JJ
Am J Cardiol; 2007 Dec; 100(11 A):n47-52. PubMed ID: 18047853
[TBL] [Abstract][Full Text] [Related]
13. Dalcetrapib: a review of Phase II data.
Robinson JG
Expert Opin Investig Drugs; 2010 Jun; 19(6):795-805. PubMed ID: 20465364
[TBL] [Abstract][Full Text] [Related]
14. Cholesteryl ester transfer protein activity and cardiovascular events in patients with chronic kidney disease stage V.
Seiler S; Schlitt A; Jiang XC; Ulrich C; Blankenberg S; Lackner KJ; Girndt M; Werdan K; Buerke M; Fliser D; Heine GH
Nephrol Dial Transplant; 2008 Nov; 23(11):3599-604. PubMed ID: 18503096
[TBL] [Abstract][Full Text] [Related]
15. Increasing high-density lipoprotein cholesterol, inhibition of cholesteryl ester transfer protein, and heart disease risk reduction.
Schaefer EJ; Asztalos BF
Am J Cardiol; 2007 Dec; 100(11 A):n25-31. PubMed ID: 18047849
[TBL] [Abstract][Full Text] [Related]
16. Cholesteryl ester transfer protein (CETP) inhibitors: is there life after torcetrapib?
Neeli H; Rader DJ
Cardiol Clin; 2008 Nov; 26(4):537-46. PubMed ID: 18929230
[TBL] [Abstract][Full Text] [Related]
17. Is high HDL cholesterol always good?
Olsson AG
Ann Med; 2009; 41(1):11-8. PubMed ID: 19085339
[TBL] [Abstract][Full Text] [Related]
18. Should we take high-density lipoprotein cholesterol levels at face value?
Leite JO; Fernandez ML
Am J Cardiovasc Drugs; 2010; 10(1):1-3. PubMed ID: 20104929
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of torcetrapib, a novel cholesteryl ester transfer protein inhibitor, in individuals with below-average high-density lipoprotein cholesterol levels.
Davidson MH; McKenney JM; Shear CL; Revkin JH
J Am Coll Cardiol; 2006 Nov; 48(9):1774-81. PubMed ID: 17084249
[TBL] [Abstract][Full Text] [Related]
20. Cholesteryl ester transfer protein TaqIB variant, high-density lipoprotein cholesterol levels, cardiovascular risk, and efficacy of pravastatin treatment: individual patient meta-analysis of 13,677 subjects.
Boekholdt SM; Sacks FM; Jukema JW; Shepherd J; Freeman DJ; McMahon AD; Cambien F; Nicaud V; de Grooth GJ; Talmud PJ; Humphries SE; Miller GJ; Eiriksdottir G; Gudnason V; Kauma H; Kakko S; Savolainen MJ; Arca M; Montali A; Liu S; Lanz HJ; Zwinderman AH; Kuivenhoven JA; Kastelein JJ
Circulation; 2005 Jan; 111(3):278-87. PubMed ID: 15655129
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]